Integrated Filing — IndAS



General information about company

Scrip Code 543233
NSE Symbol CHEMCON
MSEI Symbol NOTLISTED
ISIN INE03YM01018
Name of company Chemcon Speciality Chemicals Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 14-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 10-11-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Specialty Chemicals
Start date and time of board meeting 14-11-2025   16:00:00
End date and time of board meeting 14-11-2025   16:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 12-02-2025
Indicate Company website link for updated RPT policy of the Company https://cscpl.com/wp-content/uploads/investors-relations/policies/g-policy-on-dealing-with-related-party-transactions.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The disclosure for the default on loans and debt securities not applicable to the company.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 5,371.42 10,723.22
Other income 394.67 766.36
Total income 5,766.09 11,489.58
2 Expenses
(a) Cost of materials consumed 3,278.62 6,159.03
(b) Purchases of stock-in-trade 304.01 376.03
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (161.96) 32.55
(d) Employee benefit expense 494.19 991.85
(e) Finance costs 9.32 43.36
(f) Depreciation, depletion and amortisation expense 276.76 549.18
(f) Other Expenses
1 Other Expenses 770.93 1,700.33
Total other expenses 770.93 1,700.33
Total expenses 4,971.87 9,852.33
3 Total profit before exceptional items and tax 794.22 1,637.25
4 Exceptional items 0.00 0.00
5 Total profit before tax 794.22 1,637.25
6 Tax expense
7 Current tax 210.86 420.70
8 Deferred tax 8.71 3.19
9 Total tax expenses 219.57 423.89
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 574.65 1,213.36
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 574.65 1,213.36
17 Other comprehensive income net of taxes (5.05) (10.10)
18 Total Comprehensive Income for the period 569.60 1,203.26
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 3,663.07 3,663.07
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.57 3.31
Diluted earnings (loss) per share from continuing operations 1.57 3.31
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.57 3.31
Diluted earnings (loss) per share from continuing and discontinued operations 1.57 3.31
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. These Financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013 and read with the relevant rules issued thereunder and the other accounting principles generally accepted in India. 2. The above results have been reviewed by Audit Committee and the Board of Directors have approved the above results at their meeting held on November 14, 2025 and have been subject to a limited review by the statutory auditors of the Company. 3.The Company is in the business of manufacturing of Specialty Chemicals. There is only one reportable segment in accordance with Ind AS 108 - Operating Segments. 4.Figures of corresponding previous year/period(s) have been regrouped /rearranged wherever necessary, to make them comparable. 5.The Company has entered into a Slump Sale Agreement on October 18, 2025, for acquisition of the entire business undertaking of M/s. Shivam Petrochem Industries (Partnership Firm, a related party) as a going concern for a lump sum consideration of rs. 36.00 crore. The transaction was approved by the Board on August 5, 2025, and subsequently by the shareholders at the 36th Annual General Meeting held on September 11, 2025 6.The Company has no subsidiary/ associate / Joint Venture Company , as on September 30, 2025 7.The above Financial Results of the Company are available on the Company's website www.cscpl.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 14,417.74
Capital work-in-progress 4,653.71
Investment property 0.00
Goodwill 0.00
Other intangible assets 0.56
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 198.87
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets 8,483.58
Total non-current financial assets 8,682.45
Deferred tax assets (net) 0.00
Other non-current assets 283.33
Total non-current assets 28,037.79
2 Current assets
Inventories 7,563.16
Current financial asset
Current investments 872.06
Trade receivables, current 5,755.63
Cash and cash equivalents 1,901.25
Bank balance other than cash and cash equivalents 9,012.00
Loans, current 0.00
Other current financial assets 762.82
Total current financial assets 18,303.76
Current tax assets (net) 0.00
Other current assets 874.15
Total current assets 26,741.07
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 54,778.86
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 3,663.07
Other equity 47,606.03
Total equity attributable to owners of parent 51,269.10
Non controlling interest
Total equity 51,269.10
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 10.84
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 0.00
Total non-current financial liabilities 10.84
Provisions, non-current 103.00
Deferred tax liabilities (net) 466.69
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 580.53
Current liabilities
Current financial liabilities
Borrowings, current 15.32
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 11.41
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1,934.10
Total Trade payable 1,945.51
Other current financial liabilities 726.28
Total current financial liabilities 2,687.11
Other current liabilities 187.31
Provisions, current 38.87
Current tax liabilities (Net) 15.94
Deferred government grants, Current 0.00
Total current liabilities 2,929.23
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 3,509.76
Total equity and liabilites 54,778.86
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 6.75 13.50
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss (1.70) (3.40)
5 Total Other comprehensive income (5.05) (10.10)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 1,637.25
Adjustments for reconcile profit (loss)
Adjustments for finance costs 43.36
Adjustments for decrease (increase) in inventories 1,047.39
Adjustments for decrease (increase) in trade receivables, current (560.01)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 1,381.65
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (53.44)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 313.52
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (49.40)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 549.18
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 20.31
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 305.65
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (21.89)
Adjustments for dividend income 0.00
Adjustments for interest income 619.29
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (62.90)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow (7.08)
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 0.93
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 2,287.98
Net cash flows from (used in) operations 3,925.23
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 360.41
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 3,564.82
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 1.34
Purchase of property, plant and equipment 712.83
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 173.12
Purchase of other long-term assets 171.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 619.29
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 200.41
Net cash flows from (used in) investing activities 110.33
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 2,442.83
Payments of lease liabilities 0.00
Dividends paid 0.00
Interest paid 43.36
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (2,486.19)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 1,188.96
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 1,188.96
Cash and cash equivalents cash flow statement at beginning of period 712.29
Cash and cash equivalents cash flow statement at end of period 1,901.25





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 CHEMCON SPECIALITY CHEMICALS LIMITED Mr. Kamalkumar Rajendra Aggarwal Chairman & Managing Director Remuneration - 56.00 27.26 43.89 Textual Information(1)
2 CHEMCON SPECIALITY CHEMICALS LIMITED Mr. Naresh Vijaykumar Goyal Joint Managing Director Remuneration - 38.00 30.13 44.93 Textual Information(2)
3 CHEMCON SPECIALITY CHEMICALS LIMITED Mr. Navdeep Naresh Goyal Whole-time Director Remuneration - 18.00 4.07 4.07 Textual Information(3)
4 CHEMCON SPECIALITY CHEMICALS LIMITED Mr. Rajesh Chimanlal Gandhi Whole-time Director and Chief Financial Officer Remuneration - 24.30 3.03 3.03 Textual Information(4)
5 CHEMCON SPECIALITY CHEMICALS LIMITED Mr.. Himanshu Prafulchandra Purohit Whole-time Director Remuneration - 24.30 3.03 3.03 Textual Information(5)
6 CHEMCON SPECIALITY CHEMICALS LIMITED Mr. Shahilkumar Maheshbhai Kapatel Company Secretary & Compliance Officer Remuneration - 5.34 1.02 1.91 Textual Information(6)
7 CHEMCON SPECIALITY CHEMICALS LIMITED Mr. Bharat Chunilal Shah Independent Director Any other transaction Director Sitting Fees - 0.20 0.05 0.18 Textual Information(7)
8 CHEMCON SPECIALITY CHEMICALS LIMITED Ms. Neelu Atulkumar Shah Independent Director Any other transaction Director Sitting Fees - 0.20 0.18 0.05 Textual Information(8)
9 CHEMCON SPECIALITY CHEMICALS LIMITED Mr. Pankaj Amritlal Shah Independent Director Any other transaction Director Sitting Fees - 0.30 0.00 0.14 Textual Information(9)
10 CHEMCON SPECIALITY CHEMICALS LIMITED Mr. Lalit Ramniklal Mehta Independent Director Any other transaction Director Sitting Fees - 0.20 0.09 0.09 Textual Information(10)
11 CHEMCON SPECIALITY CHEMICALS LIMITED Mr. Ketan Bhailal Shah Independent Director Any other transaction Director Sitting Fees - 0.10 0.18 0.00 Textual Information(11)
12 CHEMCON SPECIALITY CHEMICALS LIMITED Mr. Kamalkumar Rajendra Aggarwal Chairman & Managing Director Any other transaction Rent expense 12.00 - 0.90 0.16 0.16 Textual Information(12)
13 CHEMCON SPECIALITY CHEMICALS LIMITED Ms. Minal Kamal Aggrawal Relative of Key Management Personnel Any other transaction Rent expense 12.00 - 0.90 0.14 0.14 Textual Information(13)
14 CHEMCON SPECIALITY CHEMICALS LIMITED Ms. Puja Sarman Shah Relative of Key Management Personnel Any other transaction Rent expense 12.00 - 0.90 0.14 0.14 Textual Information(14)
15 CHEMCON SPECIALITY CHEMICALS LIMITED Ms. Parul Utssav Gupta Relative of Key Management Personnel Any other transaction Rent expense 12.00 - 0.90 0.14 0.14 Textual Information(15)
16 CHEMCON SPECIALITY CHEMICALS LIMITED Super Chemical Industries Entities over which Key Management Personnel or their Relative have significant influence or Control Sale of goods or services 2,000.00 - 106.63 15.45 41.92 Textual Information(16)
17 CHEMCON SPECIALITY CHEMICALS LIMITED Shivam Petrochem Industries Entities over which Key Management Personnel or their Relative have significant influence or Control Sale of goods or services 2,000.00 - 45.31 242.24 295.57 Textual Information(17)
18 CHEMCON SPECIALITY CHEMICALS LIMITED Dtech Products Private Limited Entities over which Key Management Personnel or their Relative have significant influence or Control Sale of goods or services 2,000.00 - 0.00 180.10 67.39 Textual Information(18)
19 CHEMCON SPECIALITY CHEMICALS LIMITED Dtech Products Private Limited Entities over which Key Management Personnel or their Relative have significant influence or Control Purchase of goods or services 2,000.00 - 26.58 39.36 0.00 Textual Information(19)
20 CHEMCON SPECIALITY CHEMICALS LIMITED Medicap Healthcare Limited Entities over which Key Management Personnel or their Relative have significant influence or Control Purchase of goods or services 2,000.00 - 125.10 0.52 0.00 Textual Information(20)
21 CHEMCON SPECIALITY CHEMICALS LIMITED Medicap Industries Entities over which Key Management Personnel or their Relative have significant influence or Control Purchase of goods or services 2,000.00 - 251.83 0.00 18.55 Textual Information(21)
22 CHEMCON SPECIALITY CHEMICALS LIMITED Shivam Petrochem Industries Entities over which Key Management Personnel or their Relative have significant influence or Control Purchase of goods or services 2,000.00 - 253.94 0.00 4.65 Textual Information(22)
23 CHEMCON SPECIALITY CHEMICALS LIMITED Supertech Fabrics Private Limited Entities over which Key Management Personnel or their Relative have significant influence or Control Purchase of goods or services 2,000.00 - 0.35 0.00 0.25 Textual Information(23)
24 CHEMCON SPECIALITY CHEMICALS LIMITED Dtech Products Private Limited Entities over which Key Management Personnel or their Relative have significant influence or Control Purchase of fixed assets 2,000.00 - 6.41 29.02 0.00 Textual Information(24)
25 CHEMCON SPECIALITY CHEMICALS LIMITED Medicap Healthcare Limited Entities over which Key Management Personnel or their Relative have significant influence or Control Any other transaction Reimbursement of expenses Received 2,000.00 - 0.57 0.00 0.00 Textual Information(25)
26 CHEMCON SPECIALITY CHEMICALS LIMITED KASR Healthcare Private Limited Entities over which Key Management Personnel or their Relative have significant influence or Control Any other transaction Reimbursement of expenses Received 2,000.00 - 0.00 0.34 0.00 Textual Information(26)
Total value of transaction during the reporting period 987.26



Text Block

Textual Information(1) 1. Remuneration/Director Sitting Fees was approved by the Board of Directors and/or Shareholders as per Companies Act,2013 and rules thereon. 2. Remuneration does not include provisions made for Gratuity as it is determined on an actuarial basis for the Company as a whole.
Textual Information(2) 1. Remuneration/Director Sitting Fees was approved by the Board of Directors and/or Shareholders as per Companies Act,2013 and rules thereon. 2. Remuneration does not include provisions made for Gratuity as it is determined on an actuarial basis for the Company as a whole.
Textual Information(3) 1. Remuneration/Director Sitting Fees was approved by the Board of Directors and/or Shareholders as per Companies Act,2013 and rules thereon. 2. Remuneration does not include provisions made for Gratuity as it is determined on an actuarial basis for the Company as a whole.
Textual Information(4) 1. Remuneration/Director Sitting Fees was approved by the Board of Directors and/or Shareholders as per Companies Act,2013 and rules thereon. 2. Remuneration does not include provisions made for Gratuity as it is determined on an actuarial basis for the Company as a whole.
Textual Information(5) 1. Remuneration/Director Sitting Fees was approved by the Board of Directors and/or Shareholders as per Companies Act,2013 and rules thereon. 2. Remuneration does not include provisions made for Gratuity as it is determined on an actuarial basis for the Company as a whole.
Textual Information(6) 1. Remuneration/Director Sitting Fees was approved by the Board of Directors and/or Shareholders as per Companies Act,2013 and rules thereon. 2. Remuneration does not include provisions made for Gratuity as it is determined on an actuarial basis for the Company as a whole.
Textual Information(7) 1. Remuneration/Director Sitting Fees was approved by the Board of Directors and/or Shareholders as per Companies Act,2013 and rules thereon. 2. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable.
Textual Information(8) 1. Remuneration/Director Sitting Fees was approved by the Board of Directors and/or Shareholders as per Companies Act,2013 and rules thereon. 2. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable.
Textual Information(9) 1. Remuneration/Director Sitting Fees was approved by the Board of Directors and/or Shareholders as per Companies Act,2013 and rules thereon. 2. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable.
Textual Information(10) 1. Remuneration/Director Sitting Fees was approved by the Board of Directors and/or Shareholders as per Companies Act,2013 and rules thereon. 2. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable.
Textual Information(11) 1. Remuneration/Director Sitting Fees was approved by the Board of Directors and/or Shareholders as per Companies Act,2013 and rules thereon. 2. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable.
Textual Information(12) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year.
Textual Information(13) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year.
Textual Information(14) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year.
Textual Information(15) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year.
Textual Information(16) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year.
Textual Information(17) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year. 3.The maximum value of the transactions, in aggregate, which can be allowed with Shivam Petrochem Industries as approved by Audit Committee for one financial year is INR 2000 Lakhs
Textual Information(18) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year. 3.The maximum value of the transactions, in aggregate, which can be allowed with Dtech Products Private Limited as approved by Audit Committee for one financial year is INR 2000 Lakhs
Textual Information(19) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year.3.The maximum value of the transactions, in aggregate, which can be allowed with Dtech Products Private Limited as approved by Audit Committee for one financial year is INR 2000 Lakhs
Textual Information(20) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year. 3.The maximum value of the transactions, in aggregate, which can be allowed with Medicap Healthcare Limited as approved by Audit Committee for one financial year is INR 2000 Lakhs
Textual Information(21) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year.
Textual Information(22) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year.3.The maximum value of the transactions, in aggregate, which can be allowed with Shivam Petrochem Industries as approved by Audit Committee for one financial year is INR 2000 Lakhs
Textual Information(23) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year.
Textual Information(24) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year.3.The maximum value of the transactions, in aggregate, which can be allowed with Dtech Products Private Limited as approved by Audit Committee for one financial year is INR 2000 Lakhs
Textual Information(25) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year. 3.The maximum value of the transactions, in aggregate, which can be allowed with Medicap Healthcare Limited as approved by Audit Committee for one financial year is INR 2000 Lakhs
Textual Information(26) 1. Transactions amounts reported are exclusive of GST and closing balances reported are inclusive of GST, wherever applicable. 2. The value of the related party transaction denotes the amount approved by the Audit Committee, as applicable, for one year.